---
title: Design of a phase III, double-blind, randomised, placebo-controlled trial of
  BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
date: '2023-08-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37597969/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230820180924&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: IntroductionThere is an unmet need for new treatments for idiopathic
  pulmonary fibrosis (IPF). The oral preferential phosphodiesterase 4B inhibitor,
  BI 1015550, prevented a decline in forced vital capacity (FVC) in a phase II study
  in patients with IPF. This study design describes the subsequent pivotal phase III
  study of BI 1015550 in patients with IPF ...
disable_comments: true
---
IntroductionThere is an unmet need for new treatments for idiopathic pulmonary fibrosis (IPF). The oral preferential phosphodiesterase 4B inhibitor, BI 1015550, prevented a decline in forced vital capacity (FVC) in a phase II study in patients with IPF. This study design describes the subsequent pivotal phase III study of BI 1015550 in patients with IPF ...